First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH).

Spirk, David; Noll, Sarah; Burnier, Michel; Rimoldi, Stefano; Noll, Georg; Sudano, Isabella (2020). First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH). Frontiers in cardiovascular medicine, 7(46), p. 46. Frontiers 10.3389/fcvm.2020.00046

[img]
Preview
Text
Spirk_First line cobination therapy.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (364kB) | Preview

Background: Lowering blood pressure (BP) leads to reduced risk of stroke, myocardial infarction, and cardiovascular mortality. Single-pill combination therapies may deliver better BP control than increasing the dose of monotherapies or using more drugs separately. Objectives: The aim of the present observational study was to investigate the real-life use and the effect of first line or replacement single-pill combination therapies containing irbesartan and hydrochlorothiazide (HCTZ) on systolic BP (SBP) control rate in patients with hypertension. Methods: Overall, 780 patients with moderate or severe hypertension either untreated (289; 37%) or uncontrolled (491; 63%) with previous therapy were included in the "First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension" (FLASH) prospective Swiss national-wide cohort study. All recruited patients received single-pill antihypertensive combination therapy containing HCTZ and irbesartan. BP was measured at baseline and after 8-weeks follow-up according to guidelines. Results: Mean reductions in office systolic/diastolic BP (SBP/DBP) were 23.7 ± 13.7/11.7 ± 8.5 mmHg, with reductions of 26.9 ± 14.1/13.0 ± 8.8 mmHg or 21.8 ± 13.1/11.0 ± 8.3 mmHg when the single-pill combination of irbesartan/HCTZ was given as first line or replacement treatment, respectively (p < 0.001 for differences between first line and replacement treatment in both SBP and DBP). The guidelines-recommended goals were reached in 368 (47%), 492 (63%), and 312 (40%) patients for SBP, DBP, and SBP/DBP, respectively. The SBP control rate was higher when the combination was used as first line treatment (52 vs. 44%; p = 0.043). Overall, 145 adverse events were recorded; hypotension in 12 (1.5%) cases, hypokalaemia in 9 (1.2%), and hyperkalaemia in 3 (0.4%). Conclusions: The single-pill combination of irbesartan/HCTZ was well-tolerated and achieved substantial reductions in both systolic and diastolic BP. The SBP control rate was greater when the combination was prescribed as first line treatment as suggested by recent ESC/ESH guidelines.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Spirk, David and Rimoldi, Stefano

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2297-055X

Publisher:

Frontiers

Language:

English

Submitter:

Celine Joray

Date Deposited:

29 Jun 2020 15:22

Last Modified:

05 Jul 2020 02:43

Publisher DOI:

10.3389/fcvm.2020.00046

PubMed ID:

32292790

Uncontrolled Keywords:

blood pressure goal attainment hydrochlorothiazide hypertension single-pill combination therapy

BORIS DOI:

10.7892/boris.144906

URI:

https://boris.unibe.ch/id/eprint/144906

Actions (login required)

Edit item Edit item
Provide Feedback